Ankaferd Blood Stopper Decreases Postoperative Bleeding and Number of Transfusions in Patients Treated with Clopidogrel: A Double-blind, Placebo-controlled, Randomized Clinical Trial

Akpınar, Mehmet Beşir; Atalay, Atakan; Atalay, Hakan; Dogan, Omer Faruk

doi:10.1532/hsf.1256

Cited by 9 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antithrombin activity of ABS is important especially in cardiac surgery. ABS was shown not to have the risk of thrombin-induced thrombotic complications by cardiac surgeons during open heart surgery (14)(15)(16)(17). The demonstration of the antierythroid aggregation of ABS is an important result in terms of the antihemorrhagic effect that does not create a risk of thrombosis.…”

Section: Discussionmentioning

confidence: 99%

Effects of Ankaferd Hemostat on red blood cell aggregation: a hemorheological study

Çiftçiler¹,

Aksu²,

FALKMARKEN³

2019

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: Ankaferd hemostat (ABS; Ankaferd blood stopper, İstanbul, Turkey) is a prohemostatic agent affecting erythrocytes. The hemostatic action of ABS depends upon fibrinogen gamma chain, prothrombin, and red blood cells. The aim of this study was to assess the effects of ABS on erythrocyte aggregation via hemorheological analyses. Materials and methods: To measure erythrocyte aggregation, blood samples were obtained from healthy, nonsmoker volunteers who had not taken any medication in the previous 10 days. One mL of blood was placed into the laser-assisted optical rotational cell analyzer (LORCA), into the chamber formed by the gap between two concentric glass cylinders. The solution prepared with ABS and saline was added to blood in incremental amounts of 10 µL, 20 µL, 30 µL, 40 µL, 50 µL, 60 µL, 70 µL, and 100 µL. Erythrocyte aggregation was determined by laser-assisted optical rotational cell analyzer at 37 °C. Results: AMP was found to be 17.7 ± 2.1 au in the blood without ABS, whereas it was lower in the blood with ABS. AMP was 16.0 ± 3.3 in the ABS-added blood group. RBC aggregates did not form faster when cells contacted ABS. The t t½ value was 4.6 ± 2.6 in the ABS-added blood group and 1.9 ± 0.20 in the control group. Aggregation was faster in the control group (P = 0.03). AI, which is a combination of AMP and t½, was lowered in the ABS group (48.7 ± 12.3) compared to the control group (65.8 ± 1.6) (P = 0.02). It was notable that the γIsc max (sec-1) value of the control was higher (200 ± 106) than the ABS-added blood group (141 ± 51.0). Conclusion: ABS has antierythroid aggregation effect. ABS inhibits pathological aggregation of red blood cells. Antithrombotic clinical effects of ABS may be ascribed to the antierythroid aggregan actions of the drug.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Ankaferd Hemostat on red blood cell aggregation: a hemorheological study

Çiftçiler¹,

Aksu²,

FALKMARKEN³

2019

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

“…There are two studies regarding this issue. In both studies 25 patients were included and ABS is shown to reduce bleedings significantly (Atalay et al 2015; Akpinar et al 2015). Apart from these clinical efficiency data, unfortunately in the literature there are limited data regarding safety in tissue level.…”

Section: Discussionmentioning

confidence: 99%

“…ABS is shown to be effective and safely used in the emergent beating heart coronary artery bypass grafting (Atalay et al 2015). Moreover, ABS could control the hemorrhages in the cases who were using antiagregant treatment and undergone emergency bypass operation (Akpinar et al 2015). Besides those valuable data for the efficacy of ABS, there is no available data regarding the ultrastructural analysis of ABS at tissue level.…”

Section: Introductionmentioning

confidence: 99%

Ultrastructural analyses of the novel chimeric hemostatic agent generated via nanotechnology, ABS nanohemostat, at the renal tissue level

et al. 2016

View full text Add to dashboard Cite

Ankaferd Blood Stopper (ABS), a hemostatic agent of plant origin, has been registered for the prevention of clinical hemorrhages. Currently there is no data regarding the ultrastructural analysis of ABS at the tissue level. The aim of this study is to assess renal tissue effects via scanning electron microscopy (SEM) analyses for the ABS and ABS nanohemostat (formed by the combination of self-assembling peptide amphiphile molecules and ABS). SEM experiments were performed with FEI Nova NanoSEM 230, using the ETD detector at low vacuum mode with 30 keV beam energy. SEM analyses revealed that significant erythroid aggregation are present inside the capillary bed of the renal tissue. However, neither the signs of necrosis nor any other sign of tissue damage are evident in the surrounding renal tissue supplied by the microcapillary vasculature. Our study is important for several reasons. Firstly, in our study we used ABS nanohemostat which was recently developed. This study adds valuable information to the literature regarding ABS nanohemostat. Secondly, this study is the first ultrastructural analysis of ABS that was performed at the tissue level. Thirdly, we disclosed that ABS nanohemostat could induce vital erythroid aggregation at the renal tissue level as detected by SEM. Lastly, we detected that ABS nanohemostat causes no harm to the tissues including necrosis and any other detrimental effects.

show abstract

“…Ankaferd is the first Turkish medical product officially accredited by the Turkish Ministry of Health. Recently, ABS has been shown to produce local hemostasis by acting topically after major arterial vessel injury . Reducing the compression time during patent hemostasis by facilitating hemostasis may decrease RAO.…”

Section: Introductionmentioning

confidence: 99%

Ankaferd blood stopper as a new strategy to avoid early complications after transradial procedures: A randomized clinical trial

Görgülü

Norgaz

Sipahi

2018

J Interven Cardiology

View full text Add to dashboard Cite

show abstract

Ankaferd Blood Stopper Decreases Postoperative Bleeding and Number of Transfusions in Patients Treated with Clopidogrel: A Double-blind, Placebo-controlled, Randomized Clinical Trial

Abstract: The use of local ABS reduces bleeding, transfusion requirements of packed red blood cells, platelets and total blood units in patients premedicated with clopidogrel and ASA undergoing emergent CABG .

Cited by 9 publications

References 15 publications

Effects of Ankaferd Hemostat on red blood cell aggregation: a hemorheological study

Effects of Ankaferd Hemostat on red blood cell aggregation: a hemorheological study

Ultrastructural analyses of the novel chimeric hemostatic agent generated via nanotechnology, ABS nanohemostat, at the renal tissue level

Ankaferd blood stopper as a new strategy to avoid early complications after transradial procedures: A randomized clinical trial

Contact Info

Product

Resources

About